On August 17, 2021, the Board of Directors of Eloxx Pharmaceuticals, Inc. appointed the company’s Interim Chief Financial Officer, Daniel Geffken, to serve as the company’s Principal Accounting Officer. Mr. Geffken, who is also the Company’s Principal Financial Officer, provides services through Danforth Advisors, LLC and has served as the Company’s Interim Chief Financial Officer since April 1, 2021.